We conclude that the anti-CD20 antibody rituximab is not an ideal mAb for targeting polymer prodrugs especially in term of anti-lymphoma efficacy, but the combination therapy using separately the long-circulating polymer prodrug and rituximab could improve therapeutic results in treatment of highly aggressive lymphoma. This evidence concerns the gene MS4A1 and lymphoma.